Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publicado em
- 15 mai 2024
- Citações
- 47
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika Hamilton, Mario Campone, Sara Hurvitz, Javier Cortés, Stephen R D Johnston, Antonio Llombart, Peter A Kaufman, Masakazu Toi, Guy Jerusalem et al.
Descritores MeSH
- Aminopyridines
- Antineoplastic Combined Chemotherapy Protocols
- Benzimidazoles
- Breast Neoplasms
- Circulating Tumor DNA
- Middle Aged
- Mutation
- Receptors, Estrogen
- Tamoxifen
- Biomarkers, Tumor
Veja também
Estudos relacionados
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
- CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
- Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis
- Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis